Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

A multinational and multi-disciplinary research consortium has been awarded €11.9 million to conduct a 36-month research project during the current outbreak of Zika virus infection in Latin America and the Caribbean.

Mosquito

A multinational and multi-disciplinary research consortium has been awarded €11.9 million to conduct a 36-month research project during the current outbreak of Zika virus infection in Latin America and the Caribbean.

The European Union's Horizon 2020 Research and Innovation Programme awarded the funding to the ZIKAlliance consortium, which includes researchers from the Centre for Tropical Medicine & Global Health at the University of Oxford.

The consortium is coordinated by leading virologist Professor Xavier de Lamballerie (INSERM, IRD, Aix-Marseille University), and includes the Oswaldo Cruz Foundation (Fiocruz), the Universities of Heidelberg, Leuven, and Oxford, Erasmus Medical Center, the Leiden University Medical Center, the University of Bonn Medical Centre, Fundação Bahiana de Infectologia, and Institut Pasteur among its 52 partners, located in 18 countries.

In a global effort to combat the global threat that has affected 73 countries and territories worldwide, the consortium will bring together numerous academic disciplines to address three key objectives.

The full story is available on the Medical Sciences Division website

Similar stories

A new WWARN study supports safety of WHO recommended malaria treatment to advance elimination and reduce spread of artemisinin resistance

A new WWARN study, published in BMC Medicine, supports a World Health Organization (WHO) recommendation that a single primaquine target dose of 0.25 mg/kg is generally safe and well tolerated when given together with an ACT to treat malaria.

Routine surveillance data can provide an early warning system for antimalarial resistance in pre-elimination areas in Africa

In the first published study of its kind, a new WWARN paper in the Malaria Journal has created near-real-time maps to support antimalarial drug resistance monitoring, using routine malaria surveillance data and individually patient linked data on molecular markers of antimalarial drug resistance.

Oxford University launch new clinical trial to test a treatment for monkeypox

The team behind the world-leading RECOVERY trial of COVID-19 treatments are leading a new study investigating a potential treatment for people who have been diagnosed with monkeypox. The National Institute for Health and Care Research (NIHR) has commissioned and funded the study. The first patients have now been recruited.

Using mathematical modelling to fight malaria

Researchers have created a mathematical model to predict genetic resistance to antimalarial drugs in Africa to manage one of the biggest threats to global malarial control.

FORESFA and VIE project meetings

The Medicine Quality Research Group organised a multidisciplinary hybrid meeting at Keble College, Oxford, July 3 to 6, for the FORESFA project ‘Forensic epidemiology and impact of substandard and falsified antimicrobials on public health’, funded by a Wellcome Collaborative Award.

Incomplete reporting of COVID-19 disease severity criteria compromises meta-analysis

Patients affected by COVID-19 should be treated according to the severity of their disease. However, not all key national or international organisations define severity in the same way. This imprecision in severity assessment compromises the validity of some therapeutic recommendations. Using individual patient data would better guide and improve therapeutic recommendations for COVID-19.